CT-P47 (tocilizumab) · Avtozma

Monoclonal antibody

Biosimilar of tocilizumab

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • Giant cell arteritis (GCA) in adult patientsOutside this platform's coveragedailymed.nlm.nih.gov
  • Polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and olderOutside this platform's coveragedailymed.nlm.nih.gov
  • Active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and olderdailymed.nlm.nih.gov
  • Cytokine release syndrome (CRS)Outside this platform's coveragedailymed.nlm.nih.gov
  • Patients 2 years of age and older with active systemic juvenile idiopathic arthritisFDA label
Product first approved 2025
JP
  • Avtozma/CT-P47: RA, JIA, Castleman disease, cytokine release syndrome
Product first approved 2025pearceip.law
EU
  • Avtozma: all indications of RoActemra (RA, sJIA, pJIA, GCA, etc.)
Product first approved 2025goodwinlaw.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Rheumatoid Arthritis
Phase 1 (2)
Other / comorbidity
NCT05617183 · Celltrion
2022-11-15 – 2023-09 · Healthy Subjects
What this study did
NCT05188378 · Celltrion
2021-12-22 – 2023-01-31 · Healthy Subjects
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT07570173 · Merck Sharp & Dohme LLC
2026-05-18 – 2033-10-18 · B-cell Acute Lymphoblastic Leukemia
What this study did

Competitive landscape

This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CT-P47 (tocilizumab) (Avtozma): this drugApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 August 2025ApprovalFDA approves AVTOZMA IV for cytokine release syndrome
US, FDA · Source ↗